ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which  stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more

ASCO 2020: Savolitinib is promising for the treatment of papillary renal cell carcinoma

In a study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, the tyrosine kinase inhibitor (TKI) savolitinib was shown to be more effective and safer than sunitinib as a treatment for people with papillary renal cell carcinoma (RCC). Papillary renal cell carcinoma accounts for approximately 15% of all RCC, making […]

read more

ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer

Overall survival results from a study with a combination of savolitinib and durvalumab for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium held in San Francisco last weekend. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a […]

read more

Savolitinib shows promise in first-in-human phase 1 study in solid tumours

Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]

read more

ASCO GU 2019: Savolitinib and durvalumab in metastatic papillary kidney cancer

Results from this trial for papillary renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. Metastatic papillary RCC has poor outcomes and there is need for new treatments. In this phase 1/2 study (CALYPSO), a combination of savolitinib (MET […]

read more

Current treatment of advanced papillary renal cell carcinoma

Despite significant improvements in the treatment outcomes of clear cell renal cell carcinoma (RCC), advanced/metastatic papillary RCC continues to have limited treatment options and there is clearly an unmet need. However, it is hoped that an optimal first-line treatment for papillary RCC will be identified in the next few years through the use of molecular […]

read more

Chi-Med and AstraZeneca initiate global phase III clinical trial of savolitinib in papillary kidney cancer (SAVOIR)

Chi-Med (Hutchinson Pharma), a Hong Kong-based biotechnology company, and AstraZeneca today announced that they have initiated a global pivotal phase III clinical trial of savolitinib, a highly selective c-MET inhibitor, in c-MET-driven papillary renal cell carcinoma (pRCC) (SAVOIR).  This is the first pivotal study ever conducted in c-MET-driven pRCC. The SAVOIR trial will compare savolitinib […]

read more

Savolitinib for papillary renal cell carcinoma

Papillary renal cell carcinoma (pRCC) is the second most common type of kidney cancer, but it is rare and very little is known about the biology of pRCC. However, a subset of patients with pRCC have an alteration (mutation) in the MET gene, which may be helpful in furthering the understanding of the disease. The […]

read more
Showing all 9 results
  TOP